The liver metabolizes ipriflavone into 7-hydroxy-ipriflavone and 7-(1-carboxy-ethoxy)-isoflavone. IP and its derivatives are bound to albumin, a blood protein, and distributed to tissues throughout the body.
Most soy isoflavones are classified as plant estrogens (phytoestrogens), ipriflavone does not have estrogenic activity, and does not activate any estrogen receptors in the body.
The recommended dosage of ipriflavone is 600 mg daily.
Gastrointestinal disturbances may be avoided by taking the ipriflavone supplement with food.
The drug interactions that are additive when taking ipriflavone include bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulators.
Some sugars are metabolized because they can be broken down by enzymes in the body to provide energy, while others are not metabolized because they are not recognized by the body's enzymes or cannot be broken down effectively.
Ipriflavone may decrease lymphocyte levels. Not for those with liver disease, pregnancy/breast feeding, gastric or duodenal ulcers, kidney disease, small children.
The nutritional supplements boron, calcium, fluoride, vitamin D, vitamin K may have an additive effect when taken with ipriflavone.
Do not take ipriflavone with theophylline, azfirlukast, antipsychotics, caffeine, celecoxib, cyclobenzaprine, nifedipine, anti-inflammatories, pain relivers, tacrine, tamoxifen, warfarin.
Sugar is metabolized as a source of energy.
Ipriflavone has an inhibiting effect on a liver detoxification pathway involving an enzyme known as cytochrome P450. This effect increases both the blood levels and the effects of some drugs.
Methamphetamine is metabolized into other chemicals, and then excreted from the body in the urine.
probably the bloodstream until it is metabolized.